GPS
Leading issuer processor, Global Processing Services (GPS), today announces it has been selected by Mastercard, the leader in global payments and technology, as its chosen processing partner in its Fintech Express Programme .
The two companies have been at the forefront of the global fintech revolution, with Mastercard working in close collaboration with GPS to pioneer, challenge and disrupt the banking status quo. Together, both companies have led the innovation curve for fintech entrepreneurs, from powering the first digital bank card customers can spend on, to providing 2 series BIN sponsorship, multi-currency solutions, in-app provisioning, new form factors and agency banking.
As the Paytech Pioneer™, GPS is the only issuer processor of its kind positioned to support fintechs, challenger banks and e-wallet providers in navigating the complex payments ecosystem and supporting growth journeys from the same global platform, with a single API integration. By continuing to leverage Mastercard’s expertise, technology and global network, the partnership will further accelerate the ongoing progress in the global fintech arena.
Joanne Dewar, Chief Executive Officer of Global Processing Services, commented: “GPS and Mastercard have led the charge in the fintech industry globally over the last decade. Through its early support of nascent e-money issuance and the use of prepaid, Mastercard has created what we now know as fintech, and what we all believe is pivotal to the future of mainstream payments. Together, we have broken new ground in the fintech space, addressing real world challenges and enabling financial empowerment for everyone – this announcement officially cements our partnership.”
Launched in June 2020, GPS is already embedded into Mastercard’s Fintech Express programme alongside GPS’ partners which it processes for – Railsbank , a global Banking-as-a-Service (Baas) platform, and electronic money institution, Treezor .
The programme helps start-ups launch rapidly and expand based on their needs by providing:
- Access : obtaining a Mastercard License and accessing the global payments company’s network through a streamlined onboarding process
- Build: becoming an Express Partner by building unique tech alliances and benefitting from all the advantages that Mastercard provides
- Connect: connecting with qualified Express Partners and going live with Mastercard in a matter of days
The programme is designed for fintechs looking to add payment solutions to their suite of products, tech-savvy start-ups looking at serving a new segment, as well as established players with ambitions to innovate through partnerships. Becoming an Express Partner helps brands simplify the launching of payment solutions, shortening the process from a few months to a matter of days. Express Partners also enjoy all the benefits of becoming a Qualified Engage Partner.
Scott Abrahams, Senior Vice President, Business Development & Fintech, UK&I at Mastercard noted: “We have long worked alongside GPS, together enabling the fintech industry to thrive. We are delighted to take our partnership with them to the next level by welcoming them into our Mastercard Fintech Express programme. Our joint ambitions are to foster payments innovation and further drive the transition to a digital economy, propelling the rapid growth of fintech and providing consumers with greater choice. Our Fintech Express programme enables leading innovators such as GPS to scale at speed, cementing our position as the partner of choice for fintechs across Europe.”
Mastercard Fintech Express falls under the umbrella of Mastercard Accelerate – Mastercard’s overarching fintech platform that gives start-ups and emerging brands support and assistance for every stage of their growth and transformation, from market entry to global expansion. Mastercard Accelerate comprises four main programmes: Fintech Express , Start Path , Engage and Developers .
To find out more about the Fintech Express Programme, visit: https://eu.mastercard.com/a/eu/fintechexpressEU/ .
To find out more about GPS, visit: https://www.globalprocessing.com/
###
About Global Processing Services (GPS)
Global Processing Services (GPS) is the trusted and proven go-to payments processing partner for today’s leading challenger brands, including Revolut, Starling Bank and Curve.
Founded in 2007, GPS’s highly flexible and configurable platform places the control firmly in the hands of global fintechs, digital banks and e-wallets, enabling them to deliver rich functionality to the cardholder.
GPS is certified by Mastercard and Visa to process and manage any credit, debit or prepaid card transaction globally, with offices in London, Newcastle, Singapore, Sydney and Dubai. It is equipped to meet the stringent standards required by Tier 1 banks and has integrated with more than 40 issuing banks and operates programmes for 180+ clients in 60 countries, using over 150 currencies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005395/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release
Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom